Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats.
Karen K. Szumlinski, M Y Balogun, Isabelle M Maisonneuve, Stanley D Glick
Psychopharmacology August 1, 2000 DOI: 10.1007/s002130000478 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | Ibogaine 18-methoxycoronaridine (18-MC) |
| Dose | 40 mg/kg, IP, 19 h earlier (for 18-MC); 0, 0.25, 0.5, 1 and 2 mg/kg, IP (for methamphetamine locomotion); 2 and 4 mg/kg, IP (for methamphetamine stereotypy); 4 mg/kg daily for 7 days (chronic methamphetamine) |
| Topics | Ibogaine |
| Keywords | Stimulant misuse methamphetamine Stimulants Drug self-administration Chronic methamphetamine exposure Stimulant-driven hyperactivity Drug misuse Neuropharmacology specific compounds Agents Brain pathways Pretreatment Drug interaction Behavioral neuroscience rats Movement Repetitive behaviors Animal studies |
| Citations | 28 |
| Key points | Pretreatment with ibogaine or 18-MC enhanced methamphetamine-induced locomotion and stereotypy in rats treated chronically with methamphetamine, consistent with prior cocaine findings. |
Abstract
The phenomenon of sensitization has been theoretically implicated in mediating various aspects of drug addiction. Recent dose-response studies demonstrated that pretreatment with the putative antiaddictive agent, ibogaine (IBO), and a synthetic iboga alkaloid congener, 18-methoxycoronaridine (18-MC), increase the potency of cocaine to elicit behavioral sensitization, an effect proposed to contribute, in part, to their ability to attenuate drug self-administration. As abuse of the methylated amphetamine derivative, methamphetamine (METH), is a growing public health concern, the present study determined the interactions between IBO and 18-MC and the expression of METH-induced behavioral sensitization. The effects of pretreatment with 18-MC (40 mg/kg, IP, 19 h earlier) on the expression of METH-induced locomotion (0, 0.25, 0.5, 1 and 2 mg/kg, IP) and the effects of pretreatment with either IBO or 18-MC on the expression of METH-induced stereotypy (2 and 4 mg/kg, IP) were assessed in rats treated chronically with either METH (4 mg/kg daily for 7 days) or saline. Compared to vehicle-pretreated controls, 18-MC produced an overall enhancement in METH-induced locomotion in rats treated chronically, but not acutely, with METH. In addition, both iboga agents increased the stereotypic response to METH. Iboga agents augment both the locomotor and stereotypic effects of METH in a manner consistent with previous reports for cocaine. Thus, it appears that iboga agents interact in a similar manner with the neural mechanisms mediating motor hyperactivity induced by the chronic administration of stimulant drugs.
Comparable studies
Other preclinical and animal studies on ibogaine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Noncompetitive Functional Inhibition at Diverse, Human Nicotinic Acetylcholine Receptor Subtypes by Bupropion, Phencyclidine, and Ibogaine TE671/RD cells (human muscle-type nAChR) and SH-SY5Y neuroblastoma cells (human... | 1999 | In vitro study | |
| Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Ibogaine- or harmaline-treated rats | 1993 | Experimental animal study | |
| Effects and aftereffects of ibogaine on morphine self-administration in rats. Rats | 1991 | Preclinical experimental study | |
| Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Rats | 1994 | Experimental study | |
| Glial Cell Line-Derived Neurotrophic Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against Alcohol Consumption Rats | 2005 | Experimental study |
Citations in the library
Cited by 4
- Iboga compounds reverse the behavioural disinhibiting and corticosterone effects of acute methamphetamine: Implications for their antiaddictive properties. Pharmacology, Biochemistry, and Behavior 2001
- Differential effects of ibogaine on behavioural and dopamine sensitization to cocaine. European Journal of Pharmacology June 16, 2000
- Iboga interactions with psychomotor stimulants: panacea in the paradox? Toxicon 2001
- Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration. European Journal of Pharmacology October 1, 2008
Cites 12
- Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Research September 19, 1994
- Inhibitory effects of ibogaine on cocaine self-administration in rats. European Journal of Pharmacology September 14, 1993
- 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Research May 6, 1996
- 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. Annals of the New York Academy of Sciences September 1, 2000
- Ibogaine-like effects of noribogaine in rats. Brain Research March 25, 1996
and 7 more in the library